Novocure, the St. Helier, Jersey-based medical device company, which raised more than $158M in an IPO last year, is trying to change the way we fight cancer. Company officials say its proprietary tumor treating fields technology, marketed under the product name Optune, are a new tool in the war against some of the deadliest forms of cancer. MassDevice publisher Brian Johnson recently caught up with Doyle to discuss the technology, the company's origins and how its current concentration on glioblastoma is just the beginning.
Top comments
The DeviceTalks Podcast Network is the ultimate destination for all things #MedTech. By subscribing to this single feed, you’ll gain access to every podcast in our diverse and growing portfolio—more than a dozen unique shows featuring senior leaders, groundbreaking technology insights, and in-depth discussions on the most important topics in the medical device industry.
Each episode dives deep into critical areas like business strategy, market trends, surgical robotics, orthopedics, structural heart, neurology, and beyond. You’ll hear from leading voices at top companies—ranging from major OEMs to innovative startups—sharing their solutions, stories, and strategies for tackling the indust...